Key result
SLCO1B1, ApoE, and ABCG2 polymorphisms significantly alter rosuvastatin-induced LDL-C reduction.
Why the study?
Do polymorphisms in SLCO1B1, ApoE, and ABCG2 genes affect the lipid-lowering efficacy of rosuvastatin?
Do polymorphisms in SLCO1B1, ApoE, and ABCG2 genes affect the lipid-lowering efficacy of rosuvastatin?
Genetic polymorphisms in SLCO1B1, ApoE, and ABCG2 significantly influence the LDL-C lowering efficacy of rosuvastatin.
The lipid-lowering efficacy of rosuvastatin (especially the reduction of LDL-C level) is significantly affected by the polymorphisms of SLCO1B1 (c.388A>G), ApoE (c.388T>C, c.526C>T) and ABCG2 (c.421C>A) genes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question. Polymorphisms in the SLCO1B1, ApoE, and ABCG2 genes significantly affect the lipid-lowering efficacy, especially LDL-C reduction, of rosuvastatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: